In MYC-driven medulloblastoma, the combination of AZD1775, an inhibitor of the cell cycle checkpoint kinase WEE1, with gemcitabine, an antimetabolite that attenuates nucleotide synthesis and promotes replicative DNA damage, significantly increased cytotoxic DNA damage and resulted in full regression of murine tumor xenografts [114]. This evidence concerns the gene CHEK1 and medulloblastoma.